BRNS VS SY Stock Comparison

Performance

BRNS
10/100

BRNS returned -42.40% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

SY
100/100

SY returned 60.01% in the last 12 months. Based on SPY's performance of -11.17%, its performance is above average giving it a score of 100 of 100.

Earnings

BRNS
100/100

BRNS has missed earnings 1 times in the last 20 quarters.

SY
10/100

SY has missed earnings 9 times in the last 20 quarters.

Volatility

BRNS
50/100

BRNS has had an average amount of volatility over the last 12 months giving it a score of 50 of 100.

SY
55/100

SY has had a higher than average amount of volatility over the last 12 months giving it a score of 54 of 100.

Sentiment

BRNS

"Sentiment" not found for BRNS

SY
73/100

SY had a bullish sentiment score of 73.33% across Twitter and StockTwits over the last 12 months. It had an average of 1.40 posts, 0.00 comments, and 0.00 likes per day.

Technicals

BRNS

"Technicals" not found for BRNS

SY
43/100

SY receives a 42 of 100 based on 14 indicators. 5 are bullish, 7 are bearish.

Profit

BRNS

"Profit" not found for BRNS

SY
46/100

Out of the last 20 quarters, SY has had 12 profitable quarters and has increased their profits year over year on 4 of them.

All score calculations are broken down here to help you make more informed investing decisions

Barinthus Biotherapeutics plc American Depositary Shares Summary

Nasdaq / BRNS

Healthcare

Biotechnology

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in developing novel T cell immunotherapeutics to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. It is advancing a pipeline of product candidates across a range of therapeutic areas, including VTP-300, an immunotherapeutic candidate designed as a potential component of a functional cure for chronic HBV infection; VTP-200, a non-surgical product candidate for persistent high-risk human papillomavirus (HPV); VTP-1000, an autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease; VTP-850, a second-generation immunotherapeutic candidate designed to treat recurrent prostate cancer; and VTP-1100, a preclinical cancer candidate designed to utilize the SNAP-CI platform to treat patients with HPV-related cancer. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Harwell, the United Kingdom.

So-Young International Inc. American Depository Shares Summary

Nasdaq / SY

Healthcare

Medical - Healthcare Information Services

So-Young International Inc. operates an online platform for medical aesthetics and consumption healthcare services focusing on discretionary medical treatments in the People's Republic of China and internationally. Its platform enables users to discover content and share their own experience on medical aesthetics procedures and leads users to reserve treatment services from medical aesthetic service providers for offline treatment. The company facilitates research on medical aesthetic treatment trends; ratings and reviews on treatment experiences; and blogs under the name Beauty Diaries. It also provides reservation services in the areas of dermatology, dentistry and orthodontics, ophthalmology, physical examinations, gynecology, human papilloma virus vaccines, and postnatal care; Software as a Service; and guiding and consulting services through training programs for medical service providers. In addition, the company offers internet information and technology advisory, management consulting, and Internet culture services, as well as sells medical equipment; equipment production, sales, and agency services; and micro finance services. As of December 31, 2021, it had approximately 8,400 medical aesthetic service providers and 5,000 other consumption healthcare service providers on its platform. The company was founded in 2013 and is headquartered in Beijing, China.

Power up your portfolio